IP Library › Granted Patent US 9,222,093
Granted Patent B2
US 9,222,093 · App. 13/534,774 · Granted Dec 29, 2015

Two-way, portable riboswitch mediated gene expression control device

Inventors: Jian-Dong Huang (Hong Kong, CN); Ye Jin (Hong Kong, CN)
Assignee: THE UNIVERSITY OF HONG KONG
C12N15/63C12N15/635C12N15/67C12N15/72C12N15/115C12N2310/16C12N2310/3519C12N2320/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,222,093
App. No.
13/534,774
Granted
Dec 29, 2015
Kind
B2
Abstract

A regulatable gene expression construct comprising a nucleic acid molecule comprising a two-way riboswitch operably linked to a target sequence. Also provided is a library screening strategy for efficient creation of target-specific riboswitches. A theophylline-repressible and IPTG-inducible riboswitch device achieves portable control of gene expression control in a ‘two-way’ manner. The default state of target genes is ON; the targets are switched off by adding theophylline, and switched back to the ON-state by adding IPTG without changing growth medium. The riboswitch device regulates gene expression in a portable, adjustable, and two-way manner with a variety of scientific and biotechnological applications.

Claims (8)

1. A gene expression control device comprising:

a chloramphenicol resistance gene, linked in 5′ to 3′ orientation to a theophylline-specific aptamer fragment;

the 3′ end of the theophylline-specific aptamer fragment linked to the 5′ end of a linker portion and a 5-nt random sequence, in 5′ to 3′ orientation;

a lacI gene preceded by its native ribosome binding site; and

a native lacI-lacZ intergenic region containing four lac promoters and two LacIbs, wherein when the control device is inserted into the genome of E. coli MG1655 upstream from a translational start site of a target gene, the transcription rate of the target gene is controlled by theophylline binding to the aptamer fragment.

2. The device of claim 1 wherein the 5-nt random sequence is TGTAT, in a 5′ to 3′ orientation.

3. The device of claim 1 wherein the target gene is selected from the group consisting of a lacZ gene locus, a rpoS gene locus, and a csrB gene locus.

4. A gene expression construct comprising a chloramphenicol resistance gene, a theophylline-specific aptamer fragment, a linker portion and a 5-nt random sequence, in 5′ to 3′ orientation, a lacI gene and two LacIbs (binding sites), wherein when the construct is inserted into the genome of E. coli MG1655 in a position 5′ to the ribosome binding site of a target gene, transcription of a target gene is controlled by theophylline binding to the aptamer fragment, and transcription of the target gene is detected using standard assay methodology.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 24, 2012
From: HUANG, JIAN-DONG; JIN, YE
To: THE UNIVERSITY OF HONG KONG
Reel/Frame 029010/0920 →
Continuity (2)
Provisional Application 61503453 · Jun 30, 2011
Related Publication 20130004980A1 · Jan 3, 2013